

Infusion Therapy Plan Orders

Page 1 of 4

Name:
Kaiser Permanente Member I.D. #:
Date of Birth:

Instructions to Provider

Review orders and note any changes. All orders with \boxtimes will be placed unless otherwise noted. Please fax completed order form to the infusion center where the patient will be receiving treatment (see fax numbers at the end of this protocol). Lab orders are not included on this form – place orders via usual method. Lab monitoring is the responsibility of the ordering physician.

Please	comn	lete	all the	follo	vina:
ricuse	CUIIID	1616	un une	101101	wiiiu.

☐ Pre-Service Authorization has been obtained by Kaiser Permanente		Fax: 1-888-282-2685	Voice: 1-800-289-1363
Order Date:	Diagnosis ICD-10 code (REQUIRED):		
Weight:kg	ICD-10 description:		

General Plan Communication

- Biosimilar riTUXimab-arrx is the preferred and defaulted agent in this plan
- Standard Dosing: Administered as 2 doses of 500-1000 mg, two weeks apart (Day 1 and Day 15)
- Weekly Dosing: Administered at 375 mg/m2 once weekly for 4 weeks
- Multiple Sclerosis Dosing:
 - Administered as a dose of 1,000 mg x 1, then 500 mg every 6 months thereafter
 - o Some patients may start with a 500 mg dose x 1, then 500 mg every 6 months thereafter
 - In addition, some patients may extend the dosing frequency (e.g. every 9 12 months), depending upon clinical factors
- Warning for Hypogammaglobulinemia:
 - o RiTUXimab treatment can result in profound hypogammaglobulinemia along with increased infections in a subset of patients
 - Please obtain baseline immunoglobulins: IgG, IgM, AND IgA prior to initiation of treatment, before each cycle, and every 6 months x 2 after completion of treatment.
 - Please refer to Allergy/Asthma if 1) levels are below normal prior to starting therapy or 2) levels are low and having frequent
 infections during therapy or 3) levels remain low beyond 9 months post treatment or if 4) IgG is less than 200 mg/dL at any point.
- Special instructions/notes:

Provider Information

Baseline Monitoring Parameters

- Timing: Within 3 months prior to expected therapy initiation
- CBC with differential
- Hepatitis B Core Antibody (Total)
- Hepatitis B Surface Antigen
- Hepatitis B Surface Antibody
- Hepatitis C Screen
- HIV Screen
- Immunoglobulins (IgG, IgM, IgA)
- Quantiferon TB Gold
- Varicella Immunity Screen (if no positive immunity screening available)
 - o Not required for patients with documentation of appropriately timed vaccinations against varicella virus

Monitoring Parameters for Subsequent Infusions

- Timing: Within 1 month prior to infusion day (if subsequent infusions are scheduled more than 4 weeks apart)
- CBC with differential
- Immunoglobulins (IgG, IgM, IgA)
- Immunocompetency Panel

Provider Signature:	Date:	
Printed Name:	Phone:	Fax:

нім



Infusion Therapy Plan Orders

Printed Name:

Page 2 of 4

Name:	
Kaiser Permanente Member I.D. #:	
Date of Birth:	

dications) sodium chloride 1 mg/mL IV infusion on mg
sodium chloride 1 mg/mL IV infusion on mg
on mg
e on Day 1 and 15 dose): 50-400 mg/hr, titrated Initiate infusion rate at 50 mg/hr Slowly increase in increments of 50 mg/hr every 30 min to max of 400 mg/hr if no reaction and dose): 100-400 mg/hr, titrated Initiate infusion rate at 100 mg/hr Slowly increase in increments of 100 mg/hr every 30 minutes to max of 400 mg/hr if no reaction exaction: STOP infusion immediately Begin primary infusion to wide open rate Notify MD Monitor vital signs Administer PRN medications 30 minutes after symptoms have resolved, restart infusion at 50% of rate when reaction occurred
dose): 50-400 mg/hr, titrated Initiate infusion rate at 50 mg/hr Slowly increase in increments of 50 mg/hr every 30 min to max of 400 mg/hr if no reaction and dose): 100-400 mg/hr, titrated Initiate infusion rate at 100 mg/hr Slowly increase in increments of 100 mg/hr every 30 minutes to max of 400 mg/hr if no reaction exaction: STOP infusion immediately Begin primary infusion to wide open rate Notify MD Monitor vital signs Administer PRN medications 30 minutes after symptoms have resolved, restart infusion at 50% of rate when reaction occurred
So-400 mg/hr, titrated Initiate infusion rate at 50 mg/hr Slowly increase in increments of 50 mg/hr every 30 min to max of 400 mg/hr if no reaction and dose): 100-400 mg/hr, titrated Initiate infusion rate at 100 mg/hr Slowly increase in increments of 100 mg/hr every 30 minutes to max of 400 mg/hr if no reaction exaction: STOP infusion immediately Begin primary infusion to wide open rate Notify MD Monitor vital signs Administer PRN medications 30 minutes after symptoms have resolved, restart infusion at 50% of rate when reaction occurred
50-400 mg/hr, titrated Initiate infusion rate at 50 mg/hr Slowly increase in increments of 50 mg/hr every 30 min to max of 400 mg/hr if no reaction and dose): 100-400 mg/hr, titrated Initiate infusion rate at 100 mg/hr Slowly increase in increments of 100 mg/hr every 30 minutes to max of 400 mg/hr if no reaction exaction: STOP infusion immediately Begin primary infusion to wide open rate Notify MD Monitor vital signs Administer PRN medications 30 minutes after symptoms have resolved, restart infusion at 50% of rate when reaction occurred
Initiate infusion rate at 50 mg/hr Slowly increase in increments of 50 mg/hr every 30 min to max of 400 mg/hr if no reaction and dose): 100-400 mg/hr, titrated Initiate infusion rate at 100 mg/hr Slowly increase in increments of 100 mg/hr every 30 minutes to max of 400 mg/hr if no reaction exaction: STOP infusion immediately Begin primary infusion to wide open rate Notify MD Monitor vital signs Administer PRN medications 30 minutes after symptoms have resolved, restart infusion at 50% of rate when reaction occurred
100-400 mg/hr, titrated Initiate infusion rate at 100 mg/hr Slowly increase in increments of 100 mg/hr every 30 minutes to max of 400 mg/hr if no reaction eaction: STOP infusion immediately Begin primary infusion to wide open rate Notify MD Monitor vital signs Administer PRN medications 30 minutes after symptoms have resolved, restart infusion at 50% of rate when reaction occurred
Initiate infusion rate at 100 mg/hr Slowly increase in increments of 100 mg/hr every 30 minutes to max of 400 mg/hr if no reaction eaction: STOP infusion immediately Begin primary infusion to wide open rate Notify MD Monitor vital signs Administer PRN medications 30 minutes after symptoms have resolved, restart infusion at 50% of rate when reaction occurred
STOP infusion immediately Begin primary infusion to wide open rate Notify MD Monitor vital signs Administer PRN medications 30 minutes after symptoms have resolved, restart infusion at 50% of rate when reaction occurred
Begin primary infusion to wide open rate Notify MD Monitor vital signs Administer PRN medications 30 minutes after symptoms have resolved, restart infusion at 50% of rate when reaction occurred
cations)
sodium chloride 1 mg/mL IV infusion
75 mg/m ²
avenous
e weekly for 4 weeks
dose):
50-400 mg/hr, titrated Initiate infusion rate at 50 mg/hr Slowly increase in increments of 50 mg/hr every 30 min to max of 400 mg/hr if no reaction
equent doses):
100-400 mg/hr, titrated Initiate infusion rate at 100 mg/hr Slowly increase in increments of 100 mg/hr every 30 minutes to max of 400 mg/hr if no reaction
eaction:
STOP infusion immediately Begin primary infusion to wide open rate Notify MD Monitor vital signs
Administer PRN medications 30 minutes after symptoms have resolved, restart infusion at 50% of rate when reaction occurred a above regimen:

HIM

Phone: _____ Fax: ____



Infusion Therapy Plan Orders

Page	3	of	4
-------------	---	----	---

Name:
Kaiser Permanente Member I.D. #:
Date of Birth:

Page 3 o	of 4		_		
	MS Only: Induction Inf	usion			
	riTUXimab-arrx ir	n 0.9% sodium chlorid	e 1 mg/mL IV infusion		
	Dose:	□ 1000 mg □ 500 i	mg		
	Route:	Intravenous			
	Frequency:	Once			
	Infusion	• 50-400 mg/hr, tit			
	Rate:	Initiate infusion r	- -	6.500 (1)	
	If infusion up		n increments of 50 mg/hr every 30 mi	n to max of 400 mg/n	ir if no reaction
	ij injusion-re	lated reaction:	modiatoly		
		 STOP infusion im Begin primary inf 	usion to wide open rate		
		3) Notify MD	·		
		4) Monitor vital sign			
		5) Administer PRN r6) 30 minutes after	nedications symptoms have resolved, restart infu	sion at 50% of rate w	hen reaction occurred
	Note any cha	anges to above regimen:	symptoms have resolved, restart in a	31011 40 3070 01 1400 11	nen reaction occurred
	MS Only: Maintenance	Infusion			
	riTUXimab-arrx ir	n 0.9% sodium chlorid	e 1 mg/mL IV infusion		
	Dose:	□ 500 mg			
	Route:	Intravenous			
	Frequency:	Once			
	Infusion Rate				
		• 100-400 mg/hr, tit			
		Initiate infusion raSlowly increase in	te at 100 mg/hr increments of 100 mg/hr every 30 mi	nutes to may of 400 r	ng/hr if no reaction
	If infusion-re	lated reaction:	increments of 100 mg/m every 50 mi	nutes to max of 400 i	ng/iii ii no reaction
	ij injusion-re	STOP infusion imm	nediately		
			ision to wide open rate		
		3) Notify MD			
		4) Monitor vital signs			
		5) Administer PRN m6) 30 minutes after s	edications ymptoms have resolved, restart infus	ion at 50% of rate wh	en reaction occurred
	Note any cha	anges to above regimen:	,,		
	<u></u>				
Pre-M	eds				
⊠	acetaminophen (TYLENO	L) tablet			
	Dose: 650 mg	Route: Oral	Frequency: Once, 30 minutes prior to needed during infusion for achiness		. May also be given once as
×	cetirizine (ZYRTEC) tablet	t .			
	Dose: 10 mg	Route: Oral	Frequency: Once, 60 minutes prior t	o riTUXimab infusion	(if not taken at home)
×	methylPREDNISolone soo				
	Dose: 125 mg	Route: Intravenous	Frequency: Once, 30 minutes prior t	to riTUXimab infusion	
	Other:		Francisco Open 20 minutes prior t	ta riTI IVimah infusion	
	Dose:	Route: Oral	Frequency: Once, 30 minutes prior t	to rifuximab infusion	
Provid	der Signature:		Date	e:	
	ed Name:				Fax:



Infusion Therapy Plan Orders

Name:
Kaiser Permanente Member I.D. #:
Date of Birth:

Page 4	OT 4						
IV Line	IV Line Care						
	0.9% sodium chloride in	fusion 250 mL					
	Rate: 30 mL/hr	Route: Intravenous	Frequency: Run continuously to	keep vein open. Start peripheral IV if no central line			
Infusio	on Reaction Meds						
⋈	albuterol (PROVENTIL) r	nebulizer solution 0.083%					
	Dose: 2.5 mg	Route: Nebulization	Frequency: PRN for shortness o	f breath/wheezing			
⊠	diphenhydrAMINE (BEN	ADRYL) injectable					
	Dose: 25 mg	Route: Intravenous	Frequency: Once PRN, May report May repeat in 15 minutes if sym	eat x 1 for urticaria, pruritus, shortness of breath. ptoms not resolved.			
	EPINEPHrine (Epi-Pen) 0	.3 mg/0.3 mL IM Auto-In	jector				
	Dose: 0.3 mg Route: Intramuscular Frequency: Once PRN for anaphylaxis. Inject into lateral thigh and hold for 10 seconds. Massage the injected area. Use for patients weighing greater than 27.3 kg (60 lbs). Use amp and 1.5-inch needle for patients with BMI greater than 30. Notify physician if administered.						
⊠	MethylPREDNISolone So	od Succ (PF) Inj 125 mg (S	OLU-Medrol PF)				
	Dose: 125 mg	Route: Intravenous	Frequency: Once PRN for hypers medication	sensitivity reaction. Notify MD upon giving			
⊠	meperidine (DEMEROL)	injectable					
	Dose: 25 mg	Route: Intravenous	Frequency: Once PRN, May reperminutes if symptoms not resolve	eat x1 for shaking chills or rigors. May repeat in 15 ed.			
Nursi	ng Orders						
• Co	 Contact the prescribing provider prior to the infusion if the patient has evidence of an active infection. Contact the doctor prior to the infusion if ANC is less than 1,500/mm3 or IgG is less than 500 mg/dL. 						
Refere	ences						
RIABNI	[™] (rituximab-arrx) Injectio	on, for Intravenous Use Pr	escribing Information				
Kaiser	Permanente Infusion L	ocations					
Bellevue Medical Center 11511 NE 10th St, Bellevue, WA 98004 Fax: 425-502-3811 Phone: 425-502-3820 Capitol Hill Medical Center 201 16th Ave E, Seattle WA 98112 Olympia Medical Center 700 Lilly Road N.E., Olympia, WA 98506 Fax: 360-923-7609 Phone: 360-923-7600 Fax: 360-923-7600 Fax: 360-307-7421 Phone: 360-307-7316 Tacoma Medical Center 209 Martin Luther King Jr Way, Tacoma, WA 98405							
Fax: 200 Everence 2930 M	6-326-3624 Phone: 206-33 tt Medical Center laple St, Everett, WA 98201 5-261-1578 Phone: 425-20	26-3180 Fax: 509-43	· · · · · · · · · · · · · · · · · · ·	Fax: 253-596-3351 Phone: 253-596-3350			

Provider Signature:	Date:		
Printed Name	Phone	Fax:	